ASLAN Pharmaceuticals (NASDAQ:ASLN) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN) in a research report report published on Tuesday, Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock.

Separately, Piper Sandler restated an overweight rating and set a $10.00 price target (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a research report on Wednesday, March 13th.

ASLAN Pharmaceuticals Trading Down 7.3 %

ASLN opened at $0.42 on Tuesday. The firm has a market cap of $6.79 million, a P/E ratio of -0.15 and a beta of 1.45. ASLAN Pharmaceuticals has a 12 month low of $0.39 and a 12 month high of $4.69. The stock has a 50-day moving average of $0.60 and a 200 day moving average of $0.72.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last released its quarterly earnings results on Friday, April 12th. The company reported ($0.78) earnings per share (EPS) for the quarter. On average, research analysts forecast that ASLAN Pharmaceuticals will post -2.68 earnings per share for the current fiscal year.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.